In thyroid cancer cells, a chemopreventive non-steroidal anti-inflammatory drug, sulindac sulfide, blocks the PI3K-AKT pathway and leads to the activation of FOXO3, which increases the expression of Bim, GADD45A and p27KIP1 to promote cell cycle arrest and apoptosis [43]. Here, AKT1 is linked to thyroid cancer.